Titlebook: Anticoagulants, Antiplatelets, and Thrombolytics; Shaker A. Mousa Book 2010Latest edition Springer Science+Business Media, LLC 2010 Anti-X

considerable

Heparin and Low-Molecular Weight Heparins in Thrombosis and Beyond, focused on the plasma anti-Xa and anti-IIa pharmacodynamics of different LMWHs. Other important pharmacodynamic parameters for heparin and LMWH, including effects on vascular tissue factor pathway inhibitor (TFPI) release, inhibition of inflammation through NFκB, inhibition of key matrix-degrading

不理會

Hormones

Novel Anticoagulant Therapy: Principle and Practice,cesses, including venous thromboembolism (VTE) and inflammatory diseases. Major advances in the development of oral anticoagulants have resulted in considerable progress toward the goal of safe and effective oral anticoagulants that do not require frequent monitoring or dose adjustment and have mini

abduction

CRAB

姑姑在炫耀

Prasugrel: A Novel Platelet ADP P2Y12 Receptor Antagonist,nt. These ADP P2Y. antagonists have advantages over clopidogrel ranging from faster onset to greater and less variable inhibition of platelet function. Novel ADP P2Y. antagonists are under investigation to determine whether their use can result in improved antiplatelet activity, faster onset of acti

Euthyroid